Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

First Albany Cuts Edwards Lifesciences

First Albany cuts heart-valve maker Edwards Lifesciences (EW) to underperform from neutral.

Analyst Jason Mills says Edwards Lifesciences has halted enrollment in U.S. percutaneous aortic valve feasibility trials, admitting that the current delivery method (antegrade) has resulted in increasing complications, including some deaths.

He notes Edwards Lifesciences said it expects to restart U.S. enrollment in feasibility trials with new delivery method/catheter (retrograde) by the end of 2005. However, he still thinks FDA approval within four years, as the company expects, is unlikely.

Mills is concerned about growing tissue heart valve competition in U.S. He sees more than a 10% downside risk in Edwards Lifesciences over the next 12 months.

blog comments powered by Disqus